Boron LePore Glucophage peer-to-peer meetings increase physician scripts 20%, BLP says.
Executive Summary
BORON LEPORE GLUCOPHAGE MEETINGS PRODUCE 20% MORE SCRIPTS from physicians who attend the events, Boron LePore Chief Operating Officer Gregory Boron told the Hambrecht & Quist healthcare conference Jan. 15. Return-on-investment analyses by Bristol-Myers Squibb demonstrated "that as a direct result of doctors attending our dinner meetings, the doctor is writing almost 20% more Glucophage [prescriptions] after leaving the meeting," Boron said. The meetings were conducted after the launch of Warner-Lambert's competing oral anti-diabetic Rezulin.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth